Erik P Pioro

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2747985/publications.pdf

Version: 2024-02-01

133	7,184	109321	60623
papers	citations	35 h-index	81 g-index

136	136	136	8618
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of <scp>ALSFRSâ€R</scp> item scores in pivotal study <scp>MCI186</scp>â€19. Muscle and Nerve, 2022, 65, 180-186.	2.2	4
2	ALS risk factors: Industrial airborne chemical releases. Environmental Pollution, 2022, 295, 118658.	7.5	6
3	Airborne lead and polychlorinated biphenyls (PCBs) are associated with amyotrophic lateral sclerosis (ALS) risk in the U.S. Science of the Total Environment, 2022, 819, 153096.	8.0	9
4	Graph theory network analysis provides brain MRI evidence of a partial continuum of neurodegeneration in patients with UMN-predominant ALS and ALS-FTD. NeuroImage: Clinical, 2022, 35, 103037.	2.7	5
5	Risk factors for amyotrophic lateral sclerosis: A regional United States caseâ€control study. Muscle and Nerve, 2021, 63, 52-59.	2.2	36
6	A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 287-299.	1.7	42
7	Degeneration of gray and white matter differs between hypometabolic and hypermetabolic brain regions in a patient with ALS-FTD: a longitudinal MRIâ€‰â^'â€‰PET multimodal study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 127-132.	1.7	4
8	Generation of two induced pluripotent stem cell (iPSC) lines from an ALS patient with simultaneous mutations in KIF5A and MATR3 genes. Stem Cell Research, 2021, 50, 102141.	0.7	1
9	The Incidence of Amyotrophic Lateral Sclerosis in Ohio 2016â€“2018: The Ohio Population-Based ALS Registry. Neuroepidemiology, 2021, 55, 196-205.	2.3	5
10	Progressive arm muscle weakness in ALS follows the same sequence regardless of onset site: use of TOMS, a novel analytic method to track limb strength. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 380-387.	1.7	3
11	Somatic symptoms have negligible impact on Patient Health Questionnaireâ€9 depression scale scores in neurological patients. European Journal of Neurology, 2021, 28, 1812-1819.	3.3	5
12	Corticospinal Tract and Related Grey Matter Morphometric Shape Analysis in ALS Phenotypes: A Fractal Dimension Study. Brain Sciences, 2021, 11, 371.	2.3	7
13	Amyotrophic Lateral Sclerosis Risk, Family Income, and Fish Consumption Estimates of Mercury and Omega-3 PUFAs in the United States. International Journal of Environmental Research and Public Health, 2021, 18, 4528.	2.6	4
14	Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 1236.	9.0	46
15	Pesticides applied to crops and amyotrophic lateral sclerosis risk in the U.S. NeuroToxicology, 2021, 87, 128-135.	3.0	25
16	Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis. EMBO Molecular Medicine, 2021, 13, e12595.	6.9	13
17	Stage-specific riluzole effect in amyotrophic lateral sclerosis: a retrospective study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 140-143.	1.7	14
18	Longâ€term edaravone efficacy in amyotrophic lateral sclerosis: Postâ€hoc analyses of Study 19 (MCI186â€19). Muscle and Nerve, 2020, 61, 218-221.	2.2	51

#	Article	IF	Citations
19	Palatal myoclonus, abnormal eye movements, and olivary hypertrophy in GAD65-related disorder. Neurology, 2020, 94, 273-275.	1.1	6
20	Primary lateral sclerosis (PLS) functional rating scale: PLSâ€specific clinimetric scale. Muscle and Nerve, 2020, 61, 163-172.	2.2	17
21	Identification of a pathogenic intronic KIF5A mutation in an ALS-FTD kindred. Neurology, 2020, 95, 1015-1018.	1.1	19
22	Living With the Burden of Pseudobulbar Affect: A Qualitative Analysis of the Effects of Education on Patient Experience. Journal of Patient Experience, 2020, 7, 1324-1330.	0.9	3
23	A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole. Value in Health, 2020, 23, 1543-1551.	0.3	8
24	The NEALS primary lateral sclerosis registry. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 74-81.	1.7	5
25	Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2020, 417, 117054.	0.6	70
26	2â€Deoxyâ€2â€[¹⁸F]fluoroâ€<scp>d</scp>â€glucose positron emission tomography, cortical thickness and white matter graph network abnormalities in brains of patients with amyotrophic lateral sclerosis and frontotemporal dementia suggest early neuronopathy rather than axonopathy. European Journal of Neurology, 2020, 27, 1904-1912.	3.3	7
27	Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 509-518.	1.7	66
28	Neuroimaging in primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 18-27.	1.7	21
29	Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology, 2020, 95, e59-e69.	1.1	119
30	Unbiased MRI Analyses Identify Micropathologic Differences Between Upper Motor Neuron-Predominant ALS Phenotypes. Frontiers in Neuroscience, 2019, 13, 704.	2.8	10
31	Variation in noninvasive ventilation use in amyotrophic lateral sclerosis. Neurology, 2019, 93, e306-e316.	1.1	13
32	Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology, 2019, 92, e1610-e1623.	1.1	105
33	Longitudinal 18F-FDG PET and MRI Reveal Evolving Imaging Pathology That Corresponds to Disease Progression in a Patient With ALS-FTD. Frontiers in Neurology, 2019, 10, 234.	2.4	14
34	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Annals of Neurology, 2019, 85, 470-481.	5.3	118
35	Pattern of lung function decline in patients with amyotrophic lateral sclerosis: implications for timing of noninvasive ventilation. ERJ Open Research, 2019, 5, 00044-2019.	2.6	10
36	Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyotrophic lateral sclerosis. Muscle and Nerve, 2019, 59, 531-536.	2.2	40

#	Article	IF	Citations
37	Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a selfâ€report scale (Center for Neurologic Study Bulbar Function Scale). European Journal of Neurology, 2018, 25, 907.	3.3	33
38	MR Imagingâ€“based Estimation of Upper Motor Neuron Density in Patients with Amyotrophic Lateral Sclerosis: A Feasibility Study. Radiology, 2018, 287, 955-964.	7.3	7
39	Trajectories of impairment in amyotrophic lateral sclerosis: Insights from the Pooled Resource Openâ€Access ALS Clinical Trials cohort. Muscle and Nerve, 2018, 57, 937-945.	2.2	34
40	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	8.1	517
41	ALSUntangled 43: copper. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 472-476.	1.7	3
42	Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: A quantitative speech analysis. British Journal of Clinical Pharmacology, 2018, 84, 2849-2856.	2.4	28
43	Deconstructing progression of amyotrophic lateral sclerosis in stages: a Markov modeling approach. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 483-494.	1.7	22
44	Distal Predominance of Electrodiagnostic Abnormalities in Earlyâ€Stage Amyotrophic Lateral Sclerosis. Muscle and Nerve, 2018, 58, 389-395.	2.2	6
45	Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial. Neurotherapeutics, 2017, 14, 762-772.	4.4	73
46	ALSUntangled No. 37: Inosine*. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 309-312.	1.7	1
47	Differential involvement of corticospinal tract (CST) fibers in UMN-predominant ALS patients with or without CST hyperintensity: A diffusion tensor tractography study. NeuroImage: Clinical, 2017, 14, 574-579.	2.7	22
48	Volumetric analysis of MR images for glioma classification and their effect on brain tissues. Signal, Image and Video Processing, 2017, 11, 1337-1345.	2.7	12
49	Finger extension weakness and downbeat nystagmus motor neuron disease syndrome: A novel motor neuron disorder?. Muscle and Nerve, 2017, 56, 1164-1168.	2.2	14
50	ALSUntangled 38: L-serine. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 148-151.	1.7	3
51	Laughter, crying and sadness in ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 825-831.	1.9	33
52	ALSUntangled No. 36: Accilion. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 142-147.	1.7	1
53	Peripheral Neuropathy and Amyotrophic Lateral Sclerosis. , 2017, , 225-250.		0
54	Positron emission tomography imaging in a case of E200K mutation-related spongiform encephalopathy with non-diagnostic magnetic resonance imaging and cerebrospinal fluid testing. SAGE Open Medical Case Reports, 2017, 5, 2050313X1770034.	0.3	1

#	Article	IF	Citations
55	Optimizing muscle selection for electromyography in amyotrophic lateral sclerosis. Muscle and Nerve, 2017, 56, 36-44.	2.2	11
56	Modeling the neuroanatomic propagation of ALS in the spinal cord. AIP Conference Proceedings, 2017, , .	0.4	0
57	Modeling the neuroanatomic propagation of ALS in the spinal cord. AIP Conference Proceedings, 2017, , .	0.4	0
58	A Basic Introduction to Diffusion Tensor Imaging Mathematics and Image Processing Steps. Brain Disorders & Therapy, 2017, 06, .	0.1	10
59	Course of Decline of Lung Function Based on Tolerance to Noninvasive Ventilation in Patients with Amyotrophic Lateral Sclerosis. Chest, 2016, 149, A533.	0.8	0
60	Predictors of Survival in a Large Cohort of Patients With Amyotrophic Lateral Sclerosis. Chest, 2016, 149, A534.	0.8	0
61	Depression in ALS in a large self-reporting cohort. Neurology, 2016, 87, 1631-1632.	1.1	4
62	ALSUntangled No. 34: GM604. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 617-621.	1.7	1
63	ALSUntangled No. 35: Hyperbaric Oxygen Therapy*. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 622-624.	1.7	0
64	Depression in ALS in a large self-reporting cohort. Neurology, 2016, 86, 1031-1038.	1.1	42
65	Brain Parenchymal Fraction: A Relatively Simple MRI Measure to Clinically Distinguish ALS Phenotypes. BioMed Research International, 2015, 2015, 1-6.	1.9	7
66	Comparing brain structural MRI and metabolic FDG-PET changes in patients with ALS-FTD: â€˜the chicken or the egg?â€™ question. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 952-958.	1.9	39
67	ALSUntangled No. 29: MitoQ. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 427-429.	1.7	1
68	Disparate voxel based morphometry (VBM) results between SPM and FSL softwares in ALS patients with frontotemporal dementia: which VBM results to consider?. BMC Neurology, 2015, 15, 32.	1.8	43
69	Do preprocessing algorithms and statistical models influence voxel-based morphometry (VBM) results in amyotrophic lateral sclerosis patients? A systematic comparison of popular VBM analytical methods. Journal of Magnetic Resonance Imaging, 2014, 40, 662-667.	3.4	25
70	Distinct patterns of cortical atrophy in ALS patients with or without dementia: An MRI VBM study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 216-225.	1.7	32
71	Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nature Neuroscience, 2014, 17, 664-666.	14.8	398
72	ALSUntangled No. 26: Lunasin. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 622-626.	1.7	7

#	Article	IF	Citations
73	Review of Dextromethorphan 20Âmg/Quinidine 10Âmg (NUEDEXTAÂ®) for Pseudobulbar Affect. Neurology and Therapy, 2014, 3, 15-28.	3.2	31
74	Brain white matter diffusion tensor metrics from clinical 1.5T MRI distinguish between ALS phenotypes. Journal of Neurology, 2013, 260, 2532-2540.	3.6	25
75	T 2 relaxometry measurements in low spatial frequency brain regions differ between fast spin-echo and multiple-echo spin-echo sequences. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2013, 26, 443-450.	2.0	1
76	ALS Untangled No. 20: The Deanna Protocol. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 319-323.	1.7	19
77	Use of Intrathecal Baclofen for Treatment of Severe Spasticity in Selected Patients With Motor Neuron Disease. Neurorehabilitation and Neural Repair, 2013, 27, 828-833.	2.9	16
78	Brain White Matter Shape Changes in Amyotrophic Lateral Sclerosis (ALS): A Fractal Dimension Study. PLoS ONE, 2013, 8, e73614.	2.5	41
79	ALS Untangled No. 17: â€œWhen ALS Is Lymeâ€• Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 487-491.	2.1	6
80	Amyotrophic Lateral Sclerosis and Novel Therapeutic Strategies. Neurology Research International, 2012, 2012, 1-3.	1.3	2
81	ALSUntangled No. 16: Cannabis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 400-404.	2.1	9
82	ALSUntangled 15: Coconut Oil. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 328-330.	2.1	6
83	Current Concepts in the Pharmacotherapy of Pseudobulbar Affect. Drugs, 2011, 71, 1193-1207.	10.9	30
84	Diffusion Tensor Imaging Evaluation of Corticospinal Tract Hyperintensity in Upper Motor Neuron-Predominant ALS Patients. Journal of Aging Research, 2011, 2011, 1-9.	0.9	14
85	Eye movements in amyotrophic lateral sclerosis and its mimics: a review with illustrative cases. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 110-116.	1.9	75
86	Cervical Epidural Injection Complicated By Syrinx Formation. Spine, 2010, 35, E614-E616.	2.0	9
87	Dextromethorphan Plus Ultra Lowâ€Dose Quinidine Reduces Pseudobulbar Affect. Annals of Neurology, 2010, 68, 693-702.	5.3	324
88	Structural basis for the wobbler mouse neurodegenerative disorder caused by mutation in the Vps54 subunit of the GARP complex. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12860-12865.	7.1	67
89	A two-stage genome-wide association study of sporadic amyotrophic lateral sclerosis. Human Molecular Genetics, 2009, 18, 1524-1532.	2.9	106
90	ABNORMAL EYE MOVEMENTS IN KENNEDY DISEASE. Neurology, 2009, 72, 1528-1530.	1.1	11

#	Article	IF	Citations
91	Racing against the clock: Recognizing, differentiating, diagnosing, and referring the amyotrophic lateral sclerosis patient. Annals of Neurology, 2009, 65, S10-6.	5.3	37
92	Lack of evidence of monomer/misfolded superoxide dismutaseâ€1 in sporadic amyotrophic lateral sclerosis. Annals of Neurology, 2009, 66, 75-80.	5.3	74
93	Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Annals of Neurology, 2009, 66, 235-244.	5.3	211
94	Familial ALS with SOD1 mutation misdiagnosed with polyradiculopathy and myopathy. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 476-478.	2.1	2
95	Intrathecal baclofen for spasticityâ€related pain in amyotrophic lateral sclerosis: Efficacy and factors associated with pain relief. Muscle and Nerve, 2008, 37, 396-398.	2.2	49
96	Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology, 2008, 71, 1770-1775.	1.1	240
97	A randomized controlled trial of resistance exercise in individuals with ALS. Neurology, 2007, 68, 2003-2007.	1.1	186
98	Lack of TDP-43 abnormalities in mutant SOD1 transgenic mice shows disparity with ALS. Neuroscience Letters, 2007, 420, 128-132.	2.1	107
99	Defining and Diagnosing Involuntary Emotional Expression Disorder. CNS Spectrums, 2006, 11, 1-11.	1.2	168
100	Control of microglial neurotoxicity by the fractalkine receptor. Nature Neuroscience, 2006, 9, 917-924.	14.8	1,334
101	Motor neuronopathy with dropped hands and downbeat nystagmus: A distinctive disorder? A case report. BMC Neurology, 2006, 6, 3.	1.8	11
102	Neuroimaging in ALS and ALS with frontotemporal dementia. , 2006, , 107-131.		1
103	Dysmyelinated Lower Motor Neurons Retract and Regenerate Dysfunctional Synaptic Terminals. Journal of Neuroscience, 2004, 24, 3890-3898.	3.6	35
104	Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2003, 4, 62-73.	1.2	234
105	Chapter 4 Neuroimaging in Motor Neuron Disorders. Blue Books of Practical Neurology, 2003, 28, 73-cp1.	0.1	0
106	A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology, 2003, 61, 456-464.	1.1	197
107	Imaging: MRS/MRI/PET/SPECT: Pro. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2002, 3, S71-S71.	1.2	2
108	A 25-year-old woman with hemiparesis and a solitary brain lesion.. Cleveland Clinic Journal of Medicine, 2002, 69, 389-394.	1.3	1

#	Article	IF	Citations
109	Role of brainâ€derived neurotrophic factor in wobbler mouse motor neuron disease. Muscle and Nerve, 2001, 24, 474-480.	2.2	32
110	Effects of cardiotrophinâ€1 (CTâ€1) in a mouse motor neuron disease. Muscle and Nerve, 2001, 24, 769-777.	2.2	26
111	Development, analysis, refinement, and utility of an interdisciplinary amyotrophic lateral sclerosis database. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2001, 2, 39-46.	1.2	5
112	Antioxidant therapy in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2000, 1, S5-S15.	1.2	19
113	Proton magnetic resonance spectroscopy (1 H-MRS) in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2000, 1, S7-S16.	1.2	12
114	1H-MRS evidence of neurodegeneration and excess glutamate glutamine in ALS medulla. Neurology, 1999, 53, 71-71.	1.1	123
115	Neuronal pathology in the wobbler mouse brain revealed by in vivo proton magnetic resonance spectroscopy and immunocytochemistry. NeuroReport, 1998, 9, 3041-3046.	1.2	31
116	MR spectroscopy in amyotrophic lateral sclerosis/motor neuron disease. Journal of the Neurological Sciences, 1997, 152, s49-s53.	0.6	31
117	Genetic Transfer of the Wobbler Gene to a C57BL/6J Ã— NZB Hybrid Stock: Natural History of the Motor Neuron Disease and Response to CNTF and BDNF Cotreatment. Experimental Neurology, 1997, 148, 247-255.	4.1	13
118	Neocortical infarction in subhuman primates leads to restricted morphological damage of the cholinergic neurons in the nucleus basalis of Meynert. Brain Research, 1994, 648, 1-8.	2.2	22
119	Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology, 1994, 44, 1933-1933.	1.1	159
120	Primate nucleus basalis of meynert p75NGFR-containing cholinergic neurons are protected from retrograde degeneration by the ganglioside GM1. Neuroscience, 1993, 53, 49-56.	2.3	16
121	Long-term protective effects of human recombinant nerve growth factor and monosialoganglioside GM1 treatment on primate nucleus basalis cholinergic neurons after neocortical infarction. Neuroscience, 1993, 53, 625-637.	2.3	50
122	Similarities in the ultrastructural distribution of nerve growth factor receptor-like immunoreactivity in cerebellar Purkinje cells of the neonatal and colchicine-treated adult rat. Journal of Comparative Neurology, 1991, 305, 189-200.	1.6	18
123	Chapter 32 Injury and repair of central cholinergic neurons. Progress in Brain Research, 1990, 84, 301-311.	1.4	11
124	Distribution of nerve growth factor receptor-like immunoreactivity in the adult rat central nervous system. Effect of colchicine and correlation with the cholinergic systemâ€"II. Brainstem, cerebellum and spinal cord. Neuroscience, 1990, 34, 89-110.	2.3	143
125	Immunoelectron microscopic evidence of nerve growth factor receptor metabolism and internalization in rat nucleus basalis neurons. Brain Research, 1990, 527, 109-115.	2.2	19
126	Distribution of nerve growth factor receptor-like immunoreactivity in the adult rat central nervous system. Effect of colchicine and correlation with the cholinergic systemâ€"I. Forebrain. Neuroscience, 1990, 34, 57-87.	2.3	202

#	Article	IF	Citations
127	Purkinje cells of adult rat cerebellum express nerve growth factor receptor immunoreactivity: light microscopic observations. Brain Research, 1988, 455, 182-186.	2.2	87
128	Combined thyrotroph and lactotroph cell hyperplasia simulating prolactin-secreting pituitary adenoma in long-standing primary hypothyroidism. World Neurosurgery, 1988, 29, 218-226.	1.3	39
129	Loss of substance P immunoreactivity in the nucleus of the spinal trigeminal tract after intradural tumour compression of the trigeminal nerve. Neuroscience Letters, 1985, 58, 7-12.	2.1	6
130	Demonstration of substance P immunoreactivity in the nucleus dorsalis of human spinal cord. Neuroscience Letters, 1984, 51, 61-65.	2.1	14
131	Loss of substance P and Enkephalin immunoreactivity in the human substantia nigra after striato-pallidal infarction. Brain Research, 1984, 292, 339-347.	2.2	43
132	Time to Diagnosis and Factors Affecting Diagnostic Delay in Amyotrophic Lateral Sclerosis. , 0, , 15-34.		11
133	Genome-Wide Analyses Identify KIF5A as a Novel ALS Gene. SSRN Electronic Journal, 0, , .	0.4	4